Advanced Melanoma clinical trials

Explore recruiting advanced melanoma clinical trials.

Recruiting advanced melanoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, Open-Label, Multicenter, Non-Randomized Study Of The Efficacy And‬ Safety Of Enfortumab Vedotin In Combination With Pembrolizumab Previously Treated‬ Advanced Melanoma‬

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

Finland, Norway, Denmark, France, Italy, Austria +3 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition

Germany, Spain, France, Belgium, Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy

France, Norway, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006)

Portugal, Italy, France, Germany, Poland, Norway +9 more

Phase II and Phase III (Integrated) EU CTIS Study details

Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids. The MEMBRAINS trial

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Advanced Melanoma trials by city

Advanced Melanoma in Toronto Advanced Melanoma in Vancouver Advanced Melanoma in Montreal Advanced Melanoma in Calgary Advanced Melanoma in Edmonton Advanced Melanoma in Ottawa Advanced Melanoma in Winnipeg Advanced Melanoma in Quebec City Advanced Melanoma in Hamilton Advanced Melanoma in Kitchener Advanced Melanoma in London Advanced Melanoma in Halifax Advanced Melanoma in New York Advanced Melanoma in Los Angeles Advanced Melanoma in Chicago Advanced Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease